Intercepting Pancreatic Cancer: KRAS Inhibitors in Action

Ben Stanger, MD, Hannah Weiss Professor of Oncology at the University of Pennsylvania, discusses his team's groundbreaking study on the use of KRAS-targeted small molecules to eliminate pancreatic cancer precursor lesions (PanIN) in a preclinical mouse model. The tremendous clinical implications of intercepting cancer development using novel pharmacologic agents are highlighted.

View Dr. Stanger's manuscript here

#PancreaticCancer

#KRAS-Inhibitors

#CancerInterception

#PrecisionOncology

#PanIN